Precision BioSciences Inc

NASDAQ:DTILUnited States

Precision BioSciences, Inc. is an advanced gene editing company dedicated to improving life (DTIL) with its proprietary ARCUS genome editing platform. Using ARCUS, the Company's pipeline consists of in vivo gene editing candidates designed to deliver cures for a range of genetic and infectious diseases. The ARCUS platform develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision. ARCUS particularly generates defined outcomes due to predominant repair using homology directed repair (HDR) as opposed to non-homologous end joining (NHEJ). The Company’s in vivo gene editing programs include PBGENE-HBV, PBGENE-PMM, PBGENE-NVS, PBGENE-DMD, PBGENE-LL2, PBGENE-LL3 and iECURE-OTC. PBGENE-HBV program is designed for the potential treatment of chronic hepatitis B virus (HBV). The Company is pursuing development of PBGENE-PMM as a potential opportunity for treatment of m.3243 associated primary mitochondrial myopathy (PMM).

Contact Information

Headquarters

302 E Pettigrew St Ste A100DURHAM, NC, United States 27701-2393

Phone

919-314-5512

Fax

480-393-5553

Executives

Independent Chairman of the Board

Kevin Buehler

President, Chief Executive Officer, Director

Michael Amoroso

Chief Financial Officer

Alex Kelly

General Counsel, Secretary

Dario Scimeca

Chief Medical Officer

Alan List